Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 4/20 | 0.52 |
| ▸ | TYMS | P04818 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.32 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11824106 | 0.80 | BTN3A1 (0.59) | BTN3A1TYMSALDH1A1BBOX1LPAR3 | |
| SCHEMBL2454018 | 0.74 | BTN3A1 (0.64) | BTN3A1 | |
| SCHEMBL20699858 | 0.74 | BTN3A1 (0.52) | BTN3A1TYMSALDH1A1BBOX1LMNA | |
| SCHEMBL10911496 | 0.72 | — | — | |
| SCHEMBL10002551 | 0.70 | BTN3A1 (0.59) | BTN3A1TYMSALDH1A1LMNACYP3A4 | |
| SCHEMBL3718509 | 0.69 | — | — | |
| SCHEMBL24835115 | 0.69 | BTN3A1 (1.00) | BTN3A1 | |
| SCHEMBL1157271 | 0.69 | LPAR3 (0.44) | BTN3A1LPAR3LPAR2 | |
| SCHEMBL10002547 | 0.69 | BTN3A1 (1.00) | BTN3A1 | |
| SCHEMBL12640204 | 0.69 | BTN3A1 (1.00) | BTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240261426-A1 | CONJUGATES COMPRISING PHOSPHOANTIGENS AND THEIR USE IN THERAPY | BYONDIS B.V. (NL) | 2024-08-08 | — | — | US | disclosed |
| CN-117794581-A | Conjugates comprising phosphoantigen and their use in therapy | 拜奥迪斯私人有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20210171552-A1 | PHOSPHOANTIGEN PRODRUG COMPOUNDS | UNIVERSITY OF BIRMINGHAM (GB) | 2021-06-10 | — | — | US | disclosed |
| EP-3818064-A1 | PHOSPHOANTIGEN PRODRUG COMPOUNDS | University College Cardiff Consultants, Ltd. (GB) | 2021-05-12 | — | — | EP | disclosed |
| WO-2020008189-A1 | PHOSPHOANTIGEN PRODRUG COMPOUNDS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2020-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240261426-A1 | CONJUGATES COMPRISING PHOSPHOANTIGENS AND THEIR USE IN THERAPY | CD47, PTMS, PAG1 | BTN3A1 458/4885TYMS 276/4885ALDH1A1 4466/4885 |
| US-20210171552-A1 | PHOSPHOANTIGEN PRODRUG COMPOUNDS | CD4, CD47, CD69 | BTN3A1 711/4885TYMS 123/4885ALDH1A1 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.